Ropinirol AbZ

Ropinirol AbZ may be available in the countries listed below.

Ingredient matches for Ropinirol AbZ

Ropinirole

Ropinirole hydrochloride (a derivative of Ropinirole) is reported as an ingredient of Ropinirol AbZ in the following countries:

• Germany

International Drug Name Search

Minims Pilocarpinnitrat

Minims Pilocarpinnitrat may be available in the countries listed below.

Ingredient matches for Minims Pilocarpinnitrat

Pilocarpine

Pilocarpine nitrate (a derivative of Pilocarpine) is reported as an ingredient of Minims Pilocarpinnitrat in the following countries:

• Austria

International Drug Name Search

Clinda-saar

Clinda-saar may be available in the countries listed below.

Ingredient matches for Clinda-saar

Clindamycin

Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Clinda-saar in the following countries:

• Germany

Clindamycin hydrochloride (a derivative of Clindamycin) is reported as an ingredient of Clinda-saar in the following countries:

• Germany

International Drug Name Search

DesOwen

DesOwen is a brand name of desonide topical, approved by the FDA in the following formulation(s):

DESOWEN (desonide - cream; topical)

• 
  Manufacturer: GALDERMA LABS LP
  
  Approval date: December 14, 1984
  
  Strength(s): 0.05% ^[AB]

Has a generic version of DesOwen been approved?

Yes. The following products are equivalent to DesOwen:

desonide cream; topical

• 
  Manufacturer: TARO
  
  Approval date: June 30, 1992
  
  Strength(s): 0.05% ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DesOwen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with DesOwen.

See also...

• DesOwen Cream Consumer Information (Wolters Kluwer)
• DesOwen Cream Kit Cream Consumer Information (Wolters Kluwer)
• DesOwen Lotion Consumer Information (Wolters Kluwer)
• DesOwen Lotion Kit Lotion Consumer Information (Wolters Kluwer)
• DesOwen Consumer Information (Cerner Multum)
• DesOwen 2 oz Consumer Information (Cerner Multum)
• DesOwen 4 oz Consumer Information (Cerner Multum)
• DesOwen Lotion 4 oz Kit Consumer Information (Cerner Multum)
• Desowen Advanced Consumer Information (Micromedex)
• Desonide Cream Consumer Information (Wolters Kluwer)
• Desonide Foam Consumer Information (Wolters Kluwer)
• Desonide Gel Consumer Information (Wolters Kluwer)
• Desonide Lotion Consumer Information (Wolters Kluwer)
• Desonide topical Consumer Information (Cerner Multum)
• Pms-Desonide Advanced Consumer Information (Micromedex)
• Desonide Topical application Advanced Consumer Information (Micromedex)
• Desonide AHFS DI Monographs (ASHP)

Heparina Sodica

Heparina Sodica may be available in the countries listed below.

Ingredient matches for Heparina Sodica

Heparin

Heparin sodium salt (a derivative of Heparin) is reported as an ingredient of Heparina Sodica in the following countries:

• Argentina


• Chile


• Colombia


• Venezuela

International Drug Name Search

Marromel

Marromel may be available in the countries listed below.

Ingredient matches for Marromel

Ofloxacin

Ofloxacin is reported as an ingredient of Marromel in the following countries:

• Japan

International Drug Name Search

Alphagan P

Alphagan P is a brand name of brimonidine ophthalmic, approved by the FDA in the following formulation(s):

ALPHAGAN P (brimonidine tartrate - solution/drops; ophthalmic)

• 
  Manufacturer: ALLERGAN
  
  Approval date: March 16, 2001
  
  Strength(s): 0.15% ^[RLD][AT]


• 
  Manufacturer: ALLERGAN
  
  Approval date: August 19, 2005
  
  Strength(s): 0.1% ^[RLD]

Has a generic version of Alphagan P been approved?

A generic version of Alphagan P has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Alphagan P and have been approved by the FDA:

brimonidine tartrate solution/drops; ophthalmic

• 
  Manufacturer: ALCON PHARMS LTD
  
  Approval date: May 22, 2006
  
  Strength(s): 0.15% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alphagan P. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Aqueous ophthalmic formulations and methods for preserving same
  Patent 5,424,078
  Issued: June 13, 1995
  Inventor(s): Dziabo; Anthony J. & Ripley; Paul S.
  Assignee(s): Allergan, Inc.
  Stabilized chlorine dioxide is a preservative for ophthalmic formulations. The stabilized chlorine dioxide, when employed as a preservative ophthalmic formulations is preferably present in an amount of from about 0.0002 or about 0.002 to about 0.02 weight/volume percent. The aqueous ophthalmic formulations, in addition to the stabilized chlorine dioxide and the water which functions as a vehicle for the formulations, contains an ophthalmically acceptable tonicity component effective to maintain the osmolality of the formulation at least about 200 mOsmol/kg, and a buffer to maintain the pH of the ophthalmic formulation within an acceptable physiological range. A method for preserving aqueous ophthalmic formulations utilizing stabilized chlorine dioxide is also set forth.
  
  Patent expiration dates:
  
  
  • June 13, 2012
    
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • June 13, 2012
    
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • December 13, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Compositions containing therapeutically active components having enhanced solubility
  Patent 6,562,873
  Issued: May 13, 2003
  Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
  Assignee(s): Allergan, Inc.
  Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
  
  Patent expiration dates:
  
  
  • July 10, 2021
    
  
  
  
  • July 10, 2021
    
    ✓ 
    Drug product
  
  
  
  • January 10, 2022
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Compositions containing &agr;-2-adrenergic agonist components
  Patent 6,627,210
  Issued: September 30, 2003
  Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
  Assignee(s): Allergan, Inc.
  Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
  
  Patent expiration dates:
  
  
  • July 18, 2021
    
    ✓ 
    Drug product
  
  
  
  • January 18, 2022
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Compositions containing alpha-2-adrenergic agonist components
  Patent 6,641,834
  Issued: November 4, 2003
  Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
  Assignee(s): Allergan Sales, Inc.
  Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
  
  Patent expiration dates:
  
  
  • July 28, 2021
    
    ✓ 
    Drug product
  
  
  
  • January 28, 2022
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Compositions containing alpha-2-adrenergic agonist components
  Patent 6,673,337
  Issued: January 6, 2004
  Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
  Assignee(s): Allergan, Inc.
  Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
  
  Patent expiration dates:
  
  
  • July 26, 2021
    
    ✓ 
    Drug product
  
  
  
  • January 26, 2022
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Alphagan P Consumer Information (Wolters Kluwer)
• Alphagan P Consumer Information (Cerner Multum)
• Alphagan P Advanced Consumer Information (Micromedex)
• Alphagan P AHFS DI Monographs (ASHP)
• Brimonidine Consumer Information (Wolters Kluwer)
• Brimonidine ophthalmic Consumer Information (Cerner Multum)
• Brimonidine Ophthalmic Advanced Consumer Information (Micromedex)
• Brimonidine Tartrate AHFS DI Monographs (ASHP)

Drimen

Drimen may be available in the countries listed below.

Ingredient matches for Drimen

Dimenhydrinate

Dimenhydrinate is reported as an ingredient of Drimen in the following countries:

• Greece

International Drug Name Search

Resporito

Resporito may be available in the countries listed below.

Ingredient matches for Resporito

Labetalol

Labetalol hydrochloride (a derivative of Labetalol) is reported as an ingredient of Resporito in the following countries:

• Japan

International Drug Name Search

Apo-Flunarizine

Apo-Flunarizine may be available in the countries listed below.

Ingredient matches for Apo-Flunarizine

Flunarizine

Flunarizine dihydrochloride (a derivative of Flunarizine) is reported as an ingredient of Apo-Flunarizine in the following countries:

• Canada

International Drug Name Search